{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:16:51Z","timestamp":1792819011415,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":372,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32300667"],"award-info":[{"award-number":["32300667"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371535"],"award-info":[{"award-number":["32371535"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270125"],"award-info":[{"award-number":["82270125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018619","name":"National Program for Support of Top-notch Young Professionals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2023YFC3403401"],"award-info":[{"award-number":["2023YFC3403401"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23HC1400400"],"award-info":[{"award-number":["23HC1400400"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ymthe.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:14:54Z","timestamp":1728486894000},"page":"104-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption"],"prefix":"10.1016","volume":"33","author":[{"given":"Yanhong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanghong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenlin","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haokun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoyang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-9883","authenticated-orcid":false,"given":"Yuxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.10.003_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrneph.2012.113","article-title":"An update on primary hyperoxaluria","volume":"8","author":"Hoppe","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ymthe.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.bbadis.2012.03.004","article-title":"Primary hyperoxalurias: disorders of glyoxylate detoxification","volume":"1822","author":"Salido","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2024.10.003_bib3","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ki.2009.32","article-title":"The primary hyperoxalurias","volume":"75","author":"Hoppe","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2024.10.003_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0140-6736(87)92023-X","article-title":"Enzymological diagnosis of primary hyperoxaluria type 1 by measurement of hepatic alanine: glyoxylate aminotransferase activity","volume":"1","author":"Danpure","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.10.003_bib5","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1681\/ASN.2014070698","article-title":"Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria","volume":"26","author":"Hopp","year":"2015","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2024.10.003_bib6","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1681\/ASN.V1291986","article-title":"The primary hyperoxalurias","volume":"12","author":"Leumann","year":"2001","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2024.10.003_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.003_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ki.2009.237","article-title":"Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1","volume":"76","author":"Fargue","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2024.10.003_bib9","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1111\/j.1600-6143.2010.03271.x","article-title":"Transplantation outcomes in primary hyperoxaluria","volume":"10","author":"Bergstralh","year":"2010","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.ymthe.2024.10.003_bib10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.2215\/CJN.07430711","article-title":"Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy","volume":"7","author":"Harambat","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2024.10.003_bib11","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.ki.5001707","article-title":"Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1","volume":"70","author":"Hoppe","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2024.10.003_bib12","doi-asserted-by":"crossref","first-page":"14406","DOI":"10.1073\/pnas.1408401111","article-title":"Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1","volume":"111","author":"Miyata","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.10.003_bib13","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/TP.0b013e31816de49e","article-title":"Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type-1","volume":"85","author":"Jiang","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.ymthe.2024.10.003_bib14","doi-asserted-by":"crossref","first-page":"18249","DOI":"10.1073\/pnas.0607218103","article-title":"Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer","volume":"103","author":"Salido","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/mt.2015.224","article-title":"Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I","volume":"24","author":"Martin-Higueras","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.003_bib16","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1038\/s41467-018-07827-1","article-title":"CRISPR\/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I","volume":"9","author":"Zabaleta","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.kint.2020.04.049","article-title":"CRISPR\/Cas9-mediated metabolic pathway reprogramming in a novel humanized rat model ameliorates primary hyperoxaluria type 1","volume":"98","author":"Zheng","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2024.10.003_bib18","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54363","article-title":"Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria","volume":"9","author":"McGregor","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/jmedgenet-2014-102529","article-title":"Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria","volume":"51","author":"Frishberg","year":"2014","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.ymthe.2024.10.003_bib20","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00467-017-3741-1","article-title":"Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria","volume":"32","author":"Clifford-Mobley","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymthe.2024.10.003_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.10.003_bib22","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","article-title":"CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric \u03b20\/\u03b20 transfusion-dependent \u03b2-thalassemia","volume":"28","author":"Fu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.10.003_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2016.10.044","article-title":"CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes","volume":"168","author":"Komor","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.10.003_bib24","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of\u00a0CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In\u00a0Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2024.10.003_bib25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/gt.2015.107","article-title":"Helper-dependent adenoviral vectors for liver-directed gene therapy of primary hyperoxaluria type 1","volume":"23","author":"Castello","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.10.003_bib26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.10.003_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In\u00a0Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.003_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj6901","article-title":"In\u00a0vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy","volume":"8","author":"Han","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2024.10.003_bib30","article-title":"A base editing strategy using mRNA-LNPs for in\u00a0vivo correction of the most frequent phenylketonuria variant","volume":"5","author":"Brooks","year":"2024","journal-title":"HGG Adv."},{"key":"10.1016\/j.ymthe.2024.10.003_bib31","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2024.10.003_bib32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.24911\/JBCGenetics\/183-1542047633","article-title":"Generation of a mouse model of Primary Hyperoxaluria Type 1 via CRISPR\/Cas9 mediated gene editing","volume":"2","author":"Coughlan","year":"2019","journal-title":"J.\u00a0Biochem. Clin. Genet."},{"key":"10.1016\/j.ymthe.2024.10.003_bib33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrg3116","article-title":"Genomically humanized mice: technologies and promises","volume":"13","author":"Devoy","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2024.10.003_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12915-018-0624-2","article-title":"In\u00a0vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model","volume":"17","author":"Carreras","year":"2019","journal-title":"BMC Biol."},{"key":"10.1016\/j.ymthe.2024.10.003_bib35","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymthe.2021.05.010","article-title":"Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis","volume":"30","author":"Wen","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.003_bib36","doi-asserted-by":"crossref","first-page":"W401","DOI":"10.1093\/nar\/gku410","article-title":"CHOPCHOP: a CRISPR\/Cas9 and TALEN web tool for genome editing","volume":"42","author":"Montague","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.10.003_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gky354","article-title":"CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens","volume":"46","author":"Concordet","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/mt.2010.270","article-title":"Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer","volume":"19","author":"Salido","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.003_bib39","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3748\/wjg.v23.i10.1764","article-title":"Hyperplasia vs hypertrophy in tissue regeneration after extensive liver resection","volume":"23","author":"Marongiu","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ymthe.2024.10.003_bib40","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/j.gastro.2009.05.044","article-title":"Stem cells and liver regeneration","volume":"137","author":"Duncan","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ymthe.2024.10.003_bib41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.omtn.2023.03.008","article-title":"In\u00a0vivo genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector","volume":"32","author":"Lee","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2024.10.003_bib42","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.003_bib43","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children","volume":"24","author":"Sas","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2024.10.003_bib44","doi-asserted-by":"crossref","first-page":"993","DOI":"10.24272\/j.issn.2095-8137.2022.495","article-title":"Multiplex gene editing reduces oxalate production in primary hyperoxaluria type 1","volume":"44","author":"Zheng","year":"2023","journal-title":"Zool. Res."},{"key":"10.1016\/j.ymthe.2024.10.003_bib45","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.kint.2023.11.029","article-title":"In\u00a0vivo base editing rescues primary hyperoxaluria type 1 in rats","volume":"105","author":"Chen","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2024.10.003_bib46","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.10.003_bib47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/crispr.2021.0113","article-title":"Inference of CRISPR Edits from Sanger Trace Data","volume":"5","author":"Conant","year":"2022","journal-title":"CRISPR J."},{"key":"10.1016\/j.ymthe.2024.10.003_bib48","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","article-title":"CRISPResso2 provides accurate and rapid genome editing sequence analysis","volume":"37","author":"Clement","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.10.003_bib49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/12.5.333","article-title":"HISTOCHEMICAL RECOGNITION OF CALCIUM OXALATE","volume":"12","author":"Pizzolato","year":"1964","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.ymthe.2024.10.003_bib50","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nprot.2008.80","article-title":"A reproducible and well-tolerated method for 2\/3 partial hepatectomy in mice","volume":"3","author":"Mitchell","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ymthe.2024.10.003_bib51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.10.003_bib52","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nbt.3534","article-title":"Open-source guideseq software for analysis of GUIDE-seq data","volume":"34","author":"Tsai","year":"2016","journal-title":"Nat. Biotechnol."}],"updated-by":[{"DOI":"10.1016\/j.ymthe.2024.11.031","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000}}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:30:38Z","timestamp":1783020638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624006634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1525001624006634"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.003","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}